Bandhan BSE Healthcare Index Fund Direct Growth Review 2026: NAV, Returns, Portfolio & Should You Invest?

Bandhan BSE Healthcare Index Fund Direct Growth Plan has a NAV of ₹11.8541 as of 10 Sep 2026 and an AUM of ₹21 Cr. Its 1-year, 3-year and 5-year returns are 15.04%, 0% and 0% respectively, and the scheme sits in the High Risk category. Our view is that this is a narrow-sector index fund for investors who want healthcare exposure and can live with the sector’s sharper swings, rather than those looking for a broad market core holding.

The fund is still early in its life, having launched on 06 Sep 2024, so the longer-dated return fields do not yet carry a track record. Even so, the latest 1-year figure is positive while the benchmark has been negative over the same period, which shows a materially different short-run path. The portfolio is concentrated in large healthcare names, with Sun Pharmaceutical Industries Limited carrying the biggest individual weight.

Quick facts

Particular	Details
NAV	₹11.8541 as of 10 Sep 2026
AUM	₹21 Cr
Expense Ratio	0.22%
Launch Date	06 Sep 2024
Min SIP	₹100
Risk Category	High Risk
Benchmark	Nifty 50
Fund Category	Index Funds
Exit Load	0.25% on or before 15D, Nil after 15D
Fund Managers	Abhishek Jain, Mayuresh Nagvekar

The fund is managed by Abhishek Jain and Mayuresh Nagvekar.

Source data date: as of 10 Sep 2026

Performance

Period	Fund return	Benchmark return
1M	-0.09%	-4.06%
3M	9.12%	1.37%
1Y	15.04%	-7.31%
3Y	Data not available	Data not available
5Y	Data not available	Data not available

In the most recent month, the fund was close to flat and finished slightly lower, while the benchmark fell more sharply. That tells us the scheme has been somewhat steadier than the benchmark in the very short term, even though neither line points to a strong one-month trend.

The 3-month picture is more encouraging. The fund gained 9.12% against 1.37% for the benchmark, which suggests healthcare exposure helped over this window. That is a useful reminder that sector funds can behave very differently from a broad index over short periods, especially when the sector itself is moving in a distinct cycle.

On a 1-year basis, the fund has been ahead of the benchmark by a wide margin, with 15.04% versus -7.31%. We read that as stronger compounding at the fund level and weaker broad-market behaviour in the reference index over the same stretch. Because the scheme is young, there is not yet a 3-year or 5-year record to judge whether this outperformance is durable.

So the near-term trend is better than the benchmark, but the absence of longer history keeps the longer view open. For investors, that means the current return profile may be informative about recent sector momentum, but it should not be treated as proof of consistency.

Source data date: as of 10 Sep 2026

Should you BUY or HOLD Bandhan BSE Healthcare Index?

A fund's past returns alone don't tell you whether you should buy it today or continue holding it.

The right decision depends on factors such as your current allocation, purchase price, risk profile, investment horizon and the role this fund plays in your overall portfolio.

Already holding Bandhan BSE Healthcare Index? Thinking of investing now?

Get your portfolio analysed for FREE by SEBI-registered Investment Adviser (RIA) through Univest MF Premium

Peer comparison

Fund	1Y return	3Y return	5Y return
Bandhan BSE Healthcare Index Fund Direct Growth Plan	15.04%	Data not available	Data not available
ICICI Pru NASDAQ 100 Index Fund Direct Growth Plan	33.08%	30.07%	Data not available
Motilal Oswal Nifty India Defence Index Fund Direct Growth Plan	26.95%	Data not available	Data not available
Aditya Birla SL Nifty India Defence Index Fund Direct Growth Plan	26.94%	Data not available	Data not available
Tata Nifty Capital Markets Index Fund Direct Growth Plan	24.33%	Data not available	Data not available
Motilal Oswal Nifty Capital Market Index Fund Direct Growth Plan	23.74%	Data not available	Data not available

This assessment is prepared by Uniapps Investment Adviser Pvt. Ltd. under SEBI Registered Investment Adviser registration INA000017639.

The fund’s 1-year return is lower than the strongest peer figures in this set, while the 3-year and 5-year columns are not yet available for the fund itself. Among peers with longer records, ICICI Pru NASDAQ 100 Index Fund Direct Growth Plan has the clearest 3-year figure, but those comparison points belong to different market themes, so we read them as context rather than a like-for-like target. The short-term comparison suggests the healthcare theme has been competent, but not as strong as the best recent peer runs in this table.

Because several peers also lack 3-year and 5-year figures, the peer set tells two different stories: recent 1-year momentum is available for all six funds, while longer-term comparison is limited to only one peer with a 3-year history. That makes the current fund’s longer-term evaluation less complete than its short-term one.

Source data date: as of 10 Sep 2026

Portfolio: where your money goes

Holding	Sector	Weight
Sun Pharmaceutical Industries Limited	Healthcare	13.35%
Divi'S Laboratories Limited	Healthcare	6.38%
Apollo Hospitals Enterprise Limited	Healthcare	5.68%
Cipla Limited	Healthcare	5.18%
Max Healthcare Institute Limited	Healthcare	5.05%
Torrent Pharmaceuticals Limited	Healthcare	4.53%
DR. Reddy'S Laboratories Limited	Healthcare	4.35%
Laurus Labs Limited	Healthcare	4.33%
Lupin Limited	Healthcare	3.64%
Fortis Healthcare Limited	Healthcare	3.06%

The top 10 holdings account for approximately 55.55% of the portfolio.

To see all holdings, visit the Bandhan BSE Healthcare Index Fund Direct Growth Plan page

Sun Pharmaceutical Industries Limited is the largest holding at 13.35%, so it is likely to have greater influence on the fund than any other single name in the disclosed list. After that, the weights step down fairly steadily into the 6% to 3% range, which means the rest of the visible holdings still matter but each one has less individual impact than the top position.

The gap from the first holding to the tenth is meaningful, yet the table does not show an extreme cliff. That suggests the portfolio is not a one-stock story, but it is also not evenly spread across the covered names. The top 10 together account for 55.55% of the portfolio, and the broader portfolio contains 36 disclosed holdings, so the fund may combine a clear core of larger positions with a longer tail of smaller ones.

This kind of structure could make returns more sensitive to moves in the largest healthcare names while still leaving room for diversification across the rest of the basket. For investors, that usually means the fund may track the sector theme closely rather than behaving like a broad, market-wide equity fund.

Source data date: as of 10 Sep 2026

Who should invest

This fund suits investors who can tolerate High Risk exposure and who want a healthcare-sector allocation rather than a diversified equity core. The 1-year return has been positive and better than the benchmark, but the fund is too young to show a full 3-year or 5-year history, so longer holding-period conviction matters.

In our view, the better fit is someone with a medium-to-long horizon who understands that sector funds can move differently from the broader market. The main trade-off is accepting more concentrated sector exposure in exchange for the possibility of stronger performance when healthcare stocks are in favour.

Tax and exit load

Holding period	Tax rate	Description
Units held less than 1 year	20%	Short-term capital gains tax
Units held more than 1 year	12.5%	Long-term capital gains tax

Exit load: 0.25% on or before 15D, Nil after 15D.

There is no exit load after the holding period.

Source data date: as of 10 Sep 2026

Frequently asked questions

What is the current NAV of Bandhan BSE Healthcare Index Fund Direct Growth Plan?

The current NAV is ₹11.8541 as of 10 Sep 2026.

What are the fund’s 1-year, 3-year and 5-year returns?

The fund’s 1-year return is 15.04%, while the 3-year and 5-year returns are not yet available for this scheme.

How has the fund compared with its benchmark recently?

It has done better than the benchmark over 1 year and 3 months, while the benchmark was weaker over those same periods. Over 1 month, both were negative, but the benchmark fell more.

How does the fund compare with peers on recent returns?

Its 1-year return is lower than several peer funds in the comparison set, including the strongest recent figures shown there. The longer-term comparison is limited because most peers also do not yet have 3-year and 5-year figures.

What is the minimum SIP amount?

The minimum SIP amount is ₹100.

Who manages the fund and what is the exit load?

The fund is managed by Abhishek Jain and Mayuresh Nagvekar. The exit load is 0.25% on or before 15D, and nil after 15D.

Bottom line

Bandhan BSE Healthcare Index Fund Direct Growth Plan has started with a stronger recent pattern than its benchmark, but it does not yet have a long return history to prove consistency. The peer comparison also shows that its 1-year gain is respectable, though not the strongest in the set. With High Risk classification and a portfolio led by a few large healthcare names, this is best viewed as a focused sector allocation for investors who are comfortable with sharper theme-driven moves.

Published on 11 September 2026 at 5:44 PM IST

Explore mutual funds with Univest

Review mutual fund data, compare performance and explore fund insights on Univest.

Explore Univest

RIA disclosure

Mutual fund investments are subject to market risks. Read all scheme-related documents carefully before investing. This review is prepared by Uniapps Investment Adviser Pvt. Ltd. (earlier known as Uniapps Global Research Pvt. Ltd.) under SEBI Registered Investment Adviser registration INA000017639 for general informational purposes and is not personalized investment advice.